gp100-HLA-A*02:01 Inhibitors
1 drugsAbout gp100-HLA-A*02:01
The gp100-HLA-A*02:01 complex is formed when the gp100 antigen, overexpressed in melanoma, is presented by HLA-A*02:01. This presentation makes the cancer cell recognizable to T cells, enabling immune targeting.
The gp100-HLA-A*02:01 complex is a cancer immunotherapy target, though there is currently no genetic evidence directly linking its components to disease susceptibility.
KIMMTRAK, a biologic drug from IMMUNOCORE LTD approved in 2022, targets this complex. It is the only approved drug in this area.
Top gp100-HLA-A*02:01 Drugs
IMMUNOCORE LTD is the only company with an approved drug targeting gp100-HLA-A*02:01.
Low competition indicates high barriers to entry or limited market interest.
gp100-HLA-A*02:01 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets gp100-HLA-A*02:01, using biologic (other) modality.
The lack of modality diversity suggests an opportunity for novel therapeutic approaches.
gp100-HLA-A*02:01 Clinical Trials 13 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on gp100-HLA-A*02:01. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 0 | 1 | 3 | 0% |
| Phase 2 | 7 | 0 | 0 | 7 | - |
| Phase 3 | 2 | 0 | 0 | 2 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
gp100-HLA-A*02:01 Drug Approval Timeline (2022 - 2022)
The first and only drug, KIMMTRAK, was approved in 2022.
Recent approval suggests potential for growth, but also market saturation with current approach.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 10 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on gp100-HLA-A*02:01. A trial counts if an approved drug acting on gp100-HLA-A*02:01 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.